Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab ( (GMAB) ) has shared an update.
On September 29, 2025, Genmab A/S announced its intention to acquire Merus N.V., a clinical-stage biotechnology company, for approximately USD 8.0 billion in an all-cash transaction. This acquisition, unanimously approved by both companies’ boards, is expected to enhance Genmab’s late-stage pipeline and accelerate its transition to a wholly owned model. The addition of Merus’ lead asset, petosemtamab, which has received two Breakthrough Therapy Designations, aligns with Genmab’s strategic focus and is anticipated to drive significant growth, with potential new drug launches by 2027. The transaction is expected to close by early 2026 and is projected to be accretive to EBITDA by 2029, with substantial revenue potential thereafter.
The most recent analyst rating on (GMAB) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score is driven by strong earnings call results and positive technical indicators, highlighting robust growth prospects and market momentum. The company’s solid financial performance, despite recent revenue and cash flow challenges, supports its stability. Valuation metrics suggest the stock is undervalued, offering potential upside. The absence of significant corporate events does not impact the score.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company focused on developing innovative and differentiated antibody therapeutics. With over 25 years of experience, the company aims to improve the lives of patients through its expertise in antibody therapy development and commercialization, particularly in oncology.
Average Trading Volume: 1,273,913
Technical Sentiment Signal: Buy
Current Market Cap: $17.8B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.